These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 16966581

  • 1. Central action of increased osmolality to support blood pressure in deoxycorticosterone acetate-salt rats.
    O'Donaughy TL, Qi Y, Brooks VL.
    Hypertension; 2006 Oct; 48(4):658-63. PubMed ID: 16966581
    [Abstract] [Full Text] [Related]

  • 2. Deoxycorticosterone acetate-salt rats: hypertension and sympathoexcitation driven by increased NaCl levels.
    O'Donaughy TL, Brooks VL.
    Hypertension; 2006 Apr; 47(4):680-5. PubMed ID: 16520400
    [Abstract] [Full Text] [Related]

  • 3. Contribution of central nitric oxide to the regulation of blood pressure and sodium balance in DOCA-salt hypertension.
    Seto S, Nagao S, Ozeki S, Tetsuo H, Akahoshi M, Yano K.
    J Cardiovasc Pharmacol; 2006 May; 47(5):680-5. PubMed ID: 16775508
    [Abstract] [Full Text] [Related]

  • 4. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats.
    Nishimura M, Ohtsuka K, Sakamoto M, Nanbu A, Takahashi H, Yoshimura M.
    J Hypertens; 1998 Aug; 16(8):1175-85. PubMed ID: 9794722
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of an ET(B)-selective and a mixed ET(A/B) endothelin receptor antagonist on venomotor tone in deoxycorticosterone-salt hypertension.
    Johnson RJ, Galligan JJ, Fink GD.
    J Hypertens; 2001 Mar; 19(3):431-40. PubMed ID: 11288813
    [Abstract] [Full Text] [Related]

  • 8. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
    Li JS, Turgeon A, Schiffrin EL.
    Am J Hypertens; 1998 May; 11(5):554-62. PubMed ID: 9633791
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms of increased venous smooth muscle tone in desoxycorticosterone acetate-salt hypertension.
    Fink GD, Johnson RJ, Galligan JJ.
    Hypertension; 2000 Jan; 35(1 Pt 2):464-9. PubMed ID: 10642342
    [Abstract] [Full Text] [Related]

  • 10. 5-Hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats.
    Diaz J, Ni W, Thompson J, King A, Fink GD, Watts SW.
    J Pharmacol Exp Ther; 2008 Jun; 325(3):1031-8. PubMed ID: 18305011
    [Abstract] [Full Text] [Related]

  • 11. Role of endothelin and vasopressin in DOCA-salt hypertension.
    Yu M, Gopalakrishnan V, McNeill JR.
    Br J Pharmacol; 2001 Apr; 132(7):1447-54. PubMed ID: 11264238
    [Abstract] [Full Text] [Related]

  • 12. Effect of vasopressin antagonism on structure and mechanics of small arteries and vascular expression of endothelin-1 in deoxycorticosterone acetate salt hypertensive rats.
    Intengan HD, He G, Schiffrin EL.
    Hypertension; 1998 Oct; 32(4):770-7. PubMed ID: 9774378
    [Abstract] [Full Text] [Related]

  • 13. Paraventricular nucleus lesions attenuate the development of hypertension in DOCA/salt-treated rats.
    Nakata T, Takeda K, Itho H, Hirata M, Kawasaki S, Hayashi J, Oguro M, Sasaki S, Nakagawa M.
    Am J Hypertens; 1989 Aug; 2(8):625-30. PubMed ID: 2570597
    [Abstract] [Full Text] [Related]

  • 14. 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats.
    Watts SW, Fink GD.
    Am J Physiol; 1999 Mar; 276(3):H944-52. PubMed ID: 10070078
    [Abstract] [Full Text] [Related]

  • 15. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats.
    Maeda C, Schaan B, Oliveira E, Oliveira V, De Angelis K, Irigoyen M.
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):574-80. PubMed ID: 17581211
    [Abstract] [Full Text] [Related]

  • 16. Increased expression of magnocellular vasopressin mRNA in rats with deoxycorticosterone-acetate induced salt appetite.
    Grillo CA, Saravia F, Ferrini M, Piroli G, Roig P, García SI, de Kloet ER, De Nicola AF.
    Neuroendocrinology; 1998 Aug; 68(2):105-15. PubMed ID: 9705577
    [Abstract] [Full Text] [Related]

  • 17. Contribution of vascular and tubular effects of arginine-vasopressin to the development of deoxycorticosterone acetate (DOCA)-salt hypertension in rats.
    Hofbauer KG, Mah SC, Wood JM, Baum HP, Hänni H, Opperman JR, Kraetz J.
    J Hypertens Suppl; 1984 Dec; 2(3):S333-5. PubMed ID: 6599676
    [Abstract] [Full Text] [Related]

  • 18. Withdrawal-induced antihypertensive effect of vasopressin in Doca-salt hypertension.
    Chiu EK, McNeill JR.
    Am J Hypertens; 1989 Jun; 2(6 Pt 1):458-61. PubMed ID: 2757802
    [Abstract] [Full Text] [Related]

  • 19. Activation of vascular BK channel by tempol in DOCA-salt hypertensive rats.
    Xu H, Bian X, Watts SW, Hlavacova A.
    Hypertension; 2005 Nov; 46(5):1154-62. PubMed ID: 16216988
    [Abstract] [Full Text] [Related]

  • 20. Reduced contractile sensitivity and vasopressin receptor affinity in DOCA-salt hypertension.
    Bockman CS, Jeffries WB, Pettinger WA, Abel PW.
    Am J Physiol; 1992 Jun; 262(6 Pt 2):H1752-8. PubMed ID: 1535757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.